中金公司(03908.HK)2019年次级债券(第三期)票面利率厘定为4.12%
格隆汇11月8日丨中金公司(03908.HK)公布,公司面向合格投资者非公开发行不超过80亿元次级债券已获得上海证券交易所《关于对中国国际金融股份有限公司非公开发行次级债券挂牌转让无异议的函》(上证函[2019]246号)。此次债券由中信证券股份有限公司和东吴证券股份有限公司承销。该期债券为5年期,基础发行规模为11亿元,可超额配售不过4亿元。该期债券票面利率询价区间为3.7%-4.7%。
2019年11月7日,发行人和主承销商在网下向机构投资者进行了票面利率询价。根据网下机构投资者询价结果,经发行人和主承销商协商一致,最终确定该期次级债券发行的票面利率为4.12%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.